These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The differential glycosylation of human pro-urokinase from various recombinant mammalian cell lines does not affect activity and binding to PAI-1. Sarubbi E; Nolli ML; Robbiati F; Soffientini A; Parenti F; Cassani G Thromb Haemost; 1989 Nov; 62(3):927-33. PubMed ID: 2512681 [TBL] [Abstract][Full Text] [Related]
4. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Darras V; Thienpont M; Stump DC; Collen D Thromb Haemost; 1986 Dec; 56(3):411-4. PubMed ID: 3105111 [TBL] [Abstract][Full Text] [Related]
5. Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). Ugwu F; Van Hoef B; Bini A; Collen D; Lijnen HR Biochemistry; 1998 May; 37(20):7231-6. PubMed ID: 9585535 [TBL] [Abstract][Full Text] [Related]
6. A sensitive bioimmunoassay for thrombin-cleaved two-chain urokinase-type plasminogen activator in human body fluids. Braat EA; Nauland U; Dooijewaard G; Rijken DC Thromb Haemost; 1996 Jun; 75(6):908-14. PubMed ID: 8822585 [TBL] [Abstract][Full Text] [Related]
7. An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA. Declerck PJ; Van Keer L; Verstreken M; Collen D Thromb Haemost; 1992 Jan; 67(1):95-100. PubMed ID: 1377417 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function. Wojta J; Binder BR; Huber K; Hoover RL Thromb Haemost; 1989 Apr; 61(2):289-93. PubMed ID: 2501899 [TBL] [Abstract][Full Text] [Related]
9. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site. Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727 [TBL] [Abstract][Full Text] [Related]
10. An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein. Binnema DJ; Dooijewaard G; Turion PN Thromb Haemost; 1991 Feb; 65(2):144-8. PubMed ID: 1905069 [TBL] [Abstract][Full Text] [Related]
11. Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies. Nielsen LS; Grøndahl-Hansen J; Andreasen PA; Skriver L; Zeuthen J; Danø K J Immunoassay; 1986; 7(3):209-28. PubMed ID: 3091639 [TBL] [Abstract][Full Text] [Related]
12. Protection of single-chain urokinase-type plasminogen activator (scu-PA) in aprotinin treated cardiac surgical patients undergoing cardiopulmonary bypass. Spannagl M; Dooijewaard G; Dietrich W; Kluft C Thromb Haemost; 1995 May; 73(5):825-8. PubMed ID: 7482410 [TBL] [Abstract][Full Text] [Related]
13. Fibrin specific thrombolysis by two-chain urokinase-type plasminogen activator cleaved after arginine 156 by thrombin. Abercrombie DM; Buchinski B; Salvato KA; Vovis GF; Stump DC; Broeze RJ Thromb Haemost; 1990 Nov; 64(3):426-32. PubMed ID: 2128973 [TBL] [Abstract][Full Text] [Related]
14. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator. Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141 [TBL] [Abstract][Full Text] [Related]
15. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro. Lourenço DM; Dosne AM; Kher A; Samama M Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812 [TBL] [Abstract][Full Text] [Related]
16. A sensitive solid-phase immunosorbent assay for tissue-type plasminogen activator activity in plasma using trinitrobenzoylated poly-D-lysine as a stimulator for plasminogen activation. Petersen LC; Handest P; Brender J; Selmer J; Jørgensen M; Thorsen S Thromb Haemost; 1987 Apr; 57(2):205-11. PubMed ID: 3110997 [TBL] [Abstract][Full Text] [Related]
17. Native and non-glycosylated recombinant single-chain urokinase-type plasminogen activator are recognized by different receptor systems on rat parenchymal liver cells. van der Kaaden ME; Rijken DC; Groeneveld E; van Berkel TJ; Kuiper J Thromb Haemost; 1995 Aug; 74(2):722-9. PubMed ID: 8585013 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the in vitro fibrinolytic activities of low and high molecular weight single-chain urokinase-type plasminogen activator. de Munk GA; Groeneveld E; Rijken DC Thromb Haemost; 1993 Sep; 70(3):481-5. PubMed ID: 8259553 [TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395 [TBL] [Abstract][Full Text] [Related]
20. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. Grøndahl-Hansen J; Agerlin N; Munkholm-Larsen P; Bach F; Nielsen LS; Dombernowsky P; Danø K J Lab Clin Med; 1988 Jan; 111(1):42-51. PubMed ID: 3121772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]